{"name":"MedSIR","slug":"medsir","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Auxiliary Medicinal Product - Dexamethasone","genericName":"Auxiliary Medicinal Product - Dexamethasone","slug":"auxiliary-medicinal-product-dexamethasone","indication":"Auxiliary treatment for management of inflammation and immune-related adverse events in cancer therapy","status":"phase_3"}]}],"pipeline":[{"name":"Auxiliary Medicinal Product - Dexamethasone","genericName":"Auxiliary Medicinal Product - Dexamethasone","slug":"auxiliary-medicinal-product-dexamethasone","phase":"phase_3","mechanism":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Auxiliary treatment for management of inflammation and immune-related adverse events in cancer therapy","Supportive care in phase 3 oncology trials (specific indication dependent on parent trial)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQYzdwdkZ3YXdQelJOR1NXZ1JxNHhzQ3hGSWdla3A1WTdSdHVzeGViM0FJMDcwczc2MTRoTkplMGMyb3h6V0tobVhac1BhZnVzV1FVSFhHcElEemdVVE16ZmlpSWFiME1YNlFwWHhub0xzczNrQXN1WmNHODMzOU9Bc2JpeU9zdExKdWNzSHRZLWtnNEszS2FFM0tkZw?oc=5","date":"2025-10-07","type":"trial","source":"Fierce Biotech","summary":"Spanish oncology research group MEDSIR infuses AI into breast cancer trials - Fierce Biotech","headline":"Spanish oncology research group MEDSIR infuses AI into breast cancer trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNUXNPUFgtN2lEV1l5TVpKMmNOVTNISVFla0lNTUxCZXJQOW9hQnBNbjFiaGotVU9UT0E1cWcwR1ROX1k5eUNXZFJoYkkyLV82Q0hjaFlBNmRUM2tEY3VEWDdmTGRiWTU0Y1NUaG5rdGxJdUpudEZlTHBGNEFPazF4bWVHcjNGN29ubldUd0puQ0RZNjg5TE5tNEl6UWNJRWlRU0ZObHItWHkwaTYxSzlyeFV4dnh3ZnVaaTNKVldQdzZYc2xjWkpRaEJtdTRSOXZFY3k1RDlQWHpoeWRCdXNNTjlYUGdMS2s3?oc=5","date":"2024-12-12","type":"trial","source":"BioSpace","summary":"Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer - BioSpace","headline":"Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOd1I4emhJanpLZEdWQ3hTT2phaEotamJGNzFoV1p2VHFOMU9yZkZhYkpSMDlrcHF2MWt3ZVdLb3pOZXRkckNDa2pSR19OZ3U1VVB3WEN5YzZIUnBLMXNSS2E3eHE2QTFCWTZGc0U2YXVfSUgxd3duZWtDNjFZWUdVejFHODUxYjJBOEpPS0hsSVhoeFp6NHVDZ3R0LVBVNExxWUhCQ0Rwejd4Zk9LcEhFNXNMZm11TzZhUHZ3bWxBY2ZucEI0UXduVGxYNUxtTnVpOEt2eS13OE0tdGpYUTFPY1NXTUxvZDVlU1E?oc=5","date":"2024-09-16","type":"pipeline","source":"PR Newswire","summary":"MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers - PR Newswire","headline":"MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNOXBRaFVaMjNLeTJoUHBtZnRsNDlWX1NISFVNSWJVRTRQVTZpLXBDSEdMRXVfMzRtQjVZLXMtdEljNFNLWGpEY0N1TmdCTThTRXpJWHliX2xKcXByT2FLOXVLeEZSal9icEN1eTVJTTVpcjRmYkwteTJvckdBeUhwWno3ak0zZFJ2SS0xb09PbnVtU2tlcmhCb3VEX1hxejR6VWJ6UE1XcG4tM0hrV3AzaC1TTlF3aVpVRzVqXzRnZ2tOMThwRW96TjByVHN3djhZclFzVE9ZYks5a0Znak13V0pMOUVOSGttRkxleUFZRUJGckJ3YWc?oc=5","date":"2023-06-02","type":"trial","source":"PR Newswire","summary":"MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer - PR Newswire","headline":"MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}